GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardax Inc (OTCPK:CDXI) » Definitions » EV-to-EBIT

Cardax (Cardax) EV-to-EBIT : 0.00 (As of May. 17, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Cardax EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cardax's Enterprise Value is $0.00 Mil. Cardax's EBIT for the trailing twelve months (TTM) ended in Mar. 2021 was $-3.06 Mil. Therefore, Cardax's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for Cardax's EV-to-EBIT or its related term are showing as below:

CDXI's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 10
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cardax's Enterprise Value for the quarter that ended in Mar. 2021 was $7.14 Mil. Cardax's EBIT for the trailing twelve months (TTM) ended in Mar. 2021 was $-3.06 Mil. Cardax's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2021 was -42.83%.


Cardax EV-to-EBIT Historical Data

The historical data trend for Cardax's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardax EV-to-EBIT Chart

Cardax Annual Data
Trend Mar12 Mar13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only -5.17 -8.77 -6.60 -2.14 -2.29

Cardax Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.90 -1.57 -2.00 -2.29 -2.33

Competitive Comparison of Cardax's EV-to-EBIT

For the Biotechnology subindustry, Cardax's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardax's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardax's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cardax's EV-to-EBIT falls into.



Cardax EV-to-EBIT Calculation

Cardax's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/-3.059
=0.00

Cardax's current Enterprise Value is $0.00 Mil.
Cardax's EBIT for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardax  (OTCPK:CDXI) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cardax's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2021 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2021 ) =EBIT / Enterprise Value (Q: Mar. 2021 )
=-3.059/7.14167
=-42.83 %

Cardax's Enterprise Value for the quarter that ended in Mar. 2021 was $7.14 Mil.
Cardax's EBIT for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardax EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Cardax's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardax (Cardax) Business Description

Traded in Other Exchanges
N/A
Address
2800 Woodlawn Drive, Suite 129, Honolulu, HI, USA, 96822
Cardax Inc is a life sciences company engaged in the development of marketing, and distribution of consumer health products in the United States. The firm's platform has applications in arthritis, metabolic syndrome, liver disease, and cardiovascular disease, as well as macular degeneration and prostate disease. It is focused on the development of astaxanthin technologies. The group's product ZanthoSyn is marketed as a novel astaxanthin dietary supplement. Astaxanthin is a clinically studied ingredient with a safe anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health, and liver health. Geographically, it generates maximum revenue from the United States.
Executives
Paulson Capital Corp 10 percent owner 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Paulson Investment Company, Inc. 10 percent owner 5335 MEADOWS ROAD SUITE 465 LAKE OSWEGO OR 97035
Paulson Cardax Investments 1 Llc 10 percent owner 811 SW NAITO PKWY SUITE 300 PORTLAND OR 97204

Cardax (Cardax) Headlines

From GuruFocus

Cardax Reports 2019 Annual Results

By PRNewswire PRNewswire 03-30-2020

Cardax Reports 2017 Results

By PRNewswire PRNewswire 03-27-2018

Cardax Announces Warrant Exchange Offer

By PRNewswire PRNewswire 05-03-2018

Cardax Voluntarily Suspends SEC Reporting Obligations

By PRNewswire PRNewswire 08-11-2021

Cardax Announces Interim Results from CHASE Clinical Trial

By PRNewswire PRNewswire 09-23-2019

Cardax Reports 2018 Results

By PRNewswire PRNewswire 03-28-2019